Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

ProMIS Neurosciences Inc PMN

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.


NDAQ:PMN - Post by User

Comment by DavidKingCanadaon Jul 20, 2021 2:09pm
74 Views
Post# 33576013

RE:What's bringing us down ?

RE:What's bringing us down ?

Lets rephrase that, what has PMN done to Increase the SP? Nothing as of yet. 2021 was a great year for PR's but other than that not too much movement. 


Keep in mind, Biogen has Aducanumab and PMN has PMN310.

Any negative news for Aducanumab may be helping us in the long run. 


You will notice most people complain about Management but it is very impressive that they have managed to come from a low of 0.08 to where we are now. 

I still believe there is lots of good news over the horizon. The Jump we saw on June-07 was due to Biogens Aducanumab being Approved. There was no need for the SP to jump
other than people being excited. Buy and Hold for now! 

Just my opinion, take it with a grain of salt. 

<< Previous
Bullboard Posts
Next >>